Vascular-Stabilizing Compounds for Hemorrhage During Anticoagulant Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Thrombolytic and anticoagulant therapies often induce hemorrhage and vascular instability, such as localized edema and disruption of the blood-brain barrier function, which are not effectively addressed by existing treatments.
Innovation Solution
Administering a therapeutically effective amount of compounds, such as those represented by Formulae I, II, III, or IV, to prevent and treat hemorrhage and vascular instability induced by these therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombolytic and anticoagulant therapies are administered to prevent and dissolve blood clots, then blood clot formation is prevented and clots are dissolved, but hemorrhage and vascular instability are induced
Solution Approach 1:
The patent introduces a second compound as an intermediary agent that mediates between the thrombolytic/anticoagulant therapy and the vascular system. This intermediary compound protects the vascular endothelium and stabilizes vessels during thrombolytic therapy, preventing hemorrhage while allowing the primary therapy to function. The compound acts as a protective mediator that enables the primary treatment to proceed without its harmful side effects.
Solution Approach 2:
The patent converts the harmful effect of vascular instability and hemorrhage induced by thrombolytic therapy into a beneficial outcome by using the same therapeutic context to deliver a protective compound. The compound is administered in conjunction with thrombolytic therapy to specifically counteract the hemorrhagic side effects, thereby converting the harmful hemorrhage risk into a protected state where the benefits of clot dissolution are achieved without the detrimental bleeding complications.
2Productivity
If thrombolytic therapy is used to dissolve blood clots, then blood flow is restored, but disruption of blood brain barrier function occurs
Solution Approach 1:
The patent introduces a protective compound as an intermediary agent that specifically protects the blood-brain barrier during thrombolytic therapy. This intermediary compound maintains the integrity and stability of the blood-brain barrier while allowing thrombolytic agents to dissolve clots and restore blood flow. The compound acts as a protective mediator that prevents barrier disruption without interfering with the clot-dissolving process.
3Reliability
If anticoagulant therapy is administered to prevent blood clot formation, then clot prevention is achieved, but vascular instability and localized edema occur
Solution Approach 1:
The patent introduces a protective compound as an intermediary agent that specifically counteracts the vascular instability and edema caused by anticoagulant therapy. This intermediary compound stabilizes the vascular endothelium and prevents edema formation while allowing the anticoagulant to prevent clot formation. The compound acts as a protective mediator that enables anticoagulant therapy to proceed without its harmful vascular side effects.
Data Source
AI summary
Hemorrhage and vascular instability can be induced by thrombolytic and anti-coagulant therapies. Presented herein, in certain aspects, are methods for the treatment and/or prevention of hemorrhage and vascular instability that comprise administering a compound disclosed herein to a subject in need thereof.